Chuangmei Pharmaceutical (02289) disclosed the 2023 annual results announcement. The group achieved operating income of 44.0 during the reporting period...
According to the Zhitong Finance App, Chuangmei Pharmaceutical (02289) disclosed the 2023 annual results announcement. The group achieved operating revenue of 4.404 billion yuan (RMB, same below) during the reporting period, an increase of 5.47% over the previous year. Net profit attributable to shareholders of the parent company was 51.34 million yuan, a year-on-year decrease of 43.25%. Net profit attributable to shareholders of the parent company after deducting non-recurring profit and loss was RMB 5.04 million, an increase of 24.67% over the previous year. Basic earnings per share were $0.4754. It is proposed to pay a final dividend of $0.30 per share (tax included).
During the reporting period, the group's net profit attributable to shareholders of the parent company decreased by 43.25% year-on-year, mainly due to the fact that in 2022, the company obtained a one-time after-tax income of about 49 million yuan from land collection and storage cash compensation, and there was no such income during the reporting period. The Group's main business showed good performance. Net profit attributable to shareholders of the parent company after deducting non-recurring profit and loss increased 24.67% compared to 2022.